Eli Lilly (NYSE:LLY) and Boehringer Ingelheim Pharmaceuticals said today that its insulin glargine injection, Basaglar, is available by prescription in the U.S. Basaglar is a long-acting insulin with the same amino acid sequence as Sanofi‘s (NYSE:SNY) Lantus. The companies also offer resources for patients beginning insulin treatment, including an app for smartphones and tablets which provides […]
Eli Lilly & Co.
Eli Lilly, Express Scripts offer insulin discount program
Eli Lilly (NYSE:LLY) said it is teaming up with pharmacy benefit manager Express Scripts (NSDQ:ESRX) to offer discounts on the US pharma giant’s insulin products for uninsured patients and people with high-deductible insurance plans. The program will begin January 1, 2017 and will cover Lilly’s insulins Humalog, Humulin, and the biologic Basaglar. Lilly said it anticipates the program […]
Tax holiday could ignite more pharma M&A
(Reuters) – U.S. President-elect Donald Trump’s plan to incentivize U.S. companies to repatriate their swelling overseas cash piles could spur a new wave of dealmaking in a pharmaceutical industry seeking to buy its way into growth. For years, big U.S. drugmakers have turned to acquisitions of foreign companies to put their overseas cash to work, […]
Athenex, Lilly ink clinical collaboration for 1st oral formulation of paclitaxel
Athenex said today that it inked a clinical collaboration deal to conduct a phase Ib study for its oral form of paclitaxel, Oraxol, with Eli Lilly‘s (NYSE:LLY) vascular endothelial growth factor (VEGF) receptor 2 antagonist, Cyramza. Patients with advanced gastric and esophageal cancer will be enrolled in 2017 at sites in the U.S. and Asia, where […]
Novo Nordisk shares dive after long-term growth cut
(Reuters) — Top insulin maker Novo Nordisk (NYSE:NVO) slashed its long-term profit growth forecast today, signaling no let-up in its struggles to crack the U.S. market to which its chief executive said its commitment would not waver. The Danish firm’s shares fell by as much as 19% to a 30-month low, wiping more than $15 billion off […]
Physics-modeling software solves drug-delivery engineering problem
Software that models the laws of physics is usually used by theoretical physicists. But a multi-physics program based on “1st principles” can be used in real-world applications, as evidenced by a problem that cropped up for Eli Lilly (NYSE:LLY) while developing needle-based drug-delivery systems. Bernard McGarvey, a senior engineering advisor for the US pharma giant, said the […]
